Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited is an Indian biopharmaceutical organization based in Indore, Madhya Pradesh, established in 2002 after originating from research laboratory operations that began in 1995. The company specializes in the development, manufacture, and global supply of active pharmaceutical ingredients (APIs), focusing primarily on corticosteroids and steroidal hormones. Its core capabilities span both chemical synthesis and industrial fermentation technologies, allowing the enterprise to market its active ingredients and specialty intermediates to generic pharmaceutical manufacturers across more than 40 countries worldwide. The enterprise operates two specialized manufacturing sites near Indore, housing extensive infrastructure for organic chemical synthesis and large-scale fermentation with a combined fermentation volume of approximately 700 kilolitres. Symbiotec maintains international quality accreditations across its production units, including regulatory approvals and compliance certifications from global health authorities such as the US Food and Drug Administration (US FDA), the European Union Good Manufacturing Practice (EU-GMP), and South Korea's Ministry of Food and Drug Safety (MFDS). Beyond traditional active ingredient production, the company is expanding into contract development and manufacturing organization (CDMO) services and high-value finished dosage forms. Its strategic focus includes advanced sterile drug delivery systems, particularly double-chamber injectables, alongside complex steroidal formulations. By maintaining vertical integration across key chemical intermediates and bioprocessing steps, Symbiotec aims to strengthen its supply chain security while capturing higher operating margins in specialized therapeutic categories.

Symbiotec Pharmalab raised Rs 526.20 crore from 34 anchor investors on August 21, 2026, allocating 5,325,909 equity shares at the upper price band of Rs 988 per share. Domestic mutual funds secured approximately 60.06 percent of the total anchor allocation across 19 schemes from 11 asset management companies, led by ICICI Prudential, HDFC, and Motilal Oswal, along with key insurance institutions and foreign portfolio investors.